Physician profile
Robert P Suer
NPI 1902957400
$20,136.07
in general payments reported to CMS, 2019-2025
64 companies · $3,114 in 2025
The $3,114 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,921 · 2020: $2,140 · 2021: $3,630 · 2022: $3,043 · 2023: $3,394 · 2024: $2,894 · 2025: $3,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,401.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,873.70 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Novo Nordisk INC | $2,244.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,728.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,357.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,310.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $1,095.50 | 2019-2025 | Otezla, Repatha, Evenity |
| Arbor Pharmaceuticals, INC. | $919.73 | 2019-2021 | |
| Pfizer INC. | $807.43 | 2019-2025 | |
| Astellas Pharma US INC | $594.40 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $556.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.35 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $506.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $408.55 | 2019-2023 | Xarelto |
| Allergan, INC. | $382.11 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $352.92 | 2022-2024 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $345.46 | 2019-2025 | Eliquis |
| Axsome Therapeutics, INC. | $309.35 | 2024-2025 | Auvelity, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $307.33 | 2020-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $301.93 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.42 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $244.64 | 2021-2025 | Rexulti, Nuedexta |
| Abbott Laboratories | $224.45 | 2021-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $201.60 | 2023-2025 | Rexulti, Vyepti |
| Esperion Therapeutics, INC. | $192.34 | 2020-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.26 | 2021-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $141.82 | 2021-2022 | |
| Daiichi Sankyo INC. | $133.79 | 2019-2024 | Injectafer |
| Exact Sciences Corporation | $130.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $117.81 | 2021-2025 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $113.86 | 2021 | |
| Ironwood Pharmaceuticals, INC | $112.92 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $93.61 | 2023-2024 | Edarbi, Edarbi |
| Sanofi-Aventis U.S. LLC | $91.20 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.47 | 2022 | |
| Eisai INC. | $67.73 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $58.19 | 2019-2024 | Ajovy |
| Shield Therapeutics INC | $57.62 | 2024-2025 | |
| Philips North America LLC | $55.97 | 2022-2023 | |
| Edwards Lifesciences Corporation | $50.23 | 2025 | Sapien 3 Ultra Resilia |
| Kerecis Limited | $48.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mylan Specialty L.P. | $46.44 | 2020-2022 | |
| Biogen, INC. | $38.45 | 2021 | |
| Phathom Pharmaceuticals, INC. | $37.73 | 2023-2025 | Voquezna |
| Radius Health, INC. | $36.47 | 2019-2020 | |
| Grifols USA, LLC | $34.58 | 2024 | Prolastin-C Liquid |
| Seqirus USA INC | $32.76 | 2019-2022 | |
| Axonics, INC. | $27.86 | 2024 | Axonics, Bulkamid |
| Idorsia Pharmaceuticals US INC | $25.55 | 2022 | |
| Boston Scientific Corporation | $24.29 | 2025 | Watchman Flx |
| Avanir Pharmaceuticals, INC. | $23.03 | 2019-2020 | |
| Almatica Pharma LLC | $19.38 | 2023 | Loreev Xr |
| Dexcom, INC. | $18.73 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $18.71 | 2024 | Gemtesa |
| Amneal Pharmaceuticals LLC | $18.42 | 2023 | Unithroid |
| Nabriva Therapeutics, Plc | $15.21 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.83 | 2025 | Fanapt |
| Electromed, INC. | $14.70 | 2021 | |
| Acadia Pharmaceuticals INC | $13.99 | 2025 | Nuplazid |
| Genentech USA, INC. | $13.85 | 2021 | |
| Currax Pharmaceuticals LLC | $13.58 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.46 | 2021 | |
| Horizon Therapeutics Plc | $10.81 | 2019 | |
| Cardiovascular Systems INC. | $7.90 | 2020 | |
| Clarus Therapeutics INC. | $1.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Suer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.